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Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive
tumor microenvironment with a dense desmoplastic stroma. The expression of
β-galactoside-binding protein galectin-3 is regarded as an intrinsic tumor escape
mechanism for inhibition of tumor-infiltrating T cell function. In this study, we
demonstrated that galectin-3 is expressed by PDAC and by γδ or αβ T cells but is
only released in small amounts by either cell population. Interestingly, large amounts
of galectin-3 were released during the co-culture of allogeneic in vitro expanded or
allogeneic or autologous resting T cells with PDAC cells. By focusing on the co-culture
of tumor cells and γδ T cells, we observed that knockdown of galectin-3 in tumor
cells identified these cells as the source of secreted galectin-3. Galectin-3 released by
tumor cells or addition of physiological concentrations of recombinant galectin-3 did
neither further inhibit the impaired γδ T cell cytotoxicity against PDAC cells nor did it
induce cell death of in vitro expanded γδ T cells. Initial proliferation of resting peripheral
blood and tumor-infiltrating Vδ2-expressing γδ T cells was impaired by galectin-3 in
a cell-cell-contact dependent manner. The interaction of galectin-3 with α3β1 integrin
expressed by Vδ2 γδ T cells was involved in the inhibition of γδ T cell proliferation.
The addition of bispecific antibodies targeting γδ T cells to PDAC cells enhanced
their cytotoxic activity independent of the galectin-3 release. These results are of high
relevance in the context of an in vivo application of bispecific antibodies which can
enhance cytotoxic activity of γδ T cells against tumor cells but probably not their
proliferation when galectin-3 is present. In contrast, adoptive transfer of in vitro expanded
γδ T cells together with bispecific antibodies will enhance γδ T cell cytotoxicity and
overcomes the immunosuppressive function of galectin-3.
Keywords: T cells, gammadelta T cells, pancreatic cancer, galectin-3, α3β1 integrin, bispecific antibodies,
proliferation, autologous
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INTRODUCTION
Galectin (gal)-3 is a member of β-galactoside-binding protein
family that shares highly conserved carbohydrate recognition
domains (CRD) (1, 2). The monomer gal-3 belongs to the
chimera-type subgroup of the galectin family which contains one
CRD that is connected to an extended non-lectin N-terminal
domain. This exclusive gal-3 structure allows dimerization in
the absence of binding ligands and a formation of pentamers in
the presence of carbohydrate binding ligands such as N-glycans
(3). As a multifunctional protein, gal-3 is involved in cell-matrix
adhesion, cell proliferation, cell death, receptor turnover, and cell
signaling as well as in malignant transformation depending on
its subcellular localization (1–4). Gal-3 is found in the cytoplasm,
shuttles between the cytoplasm and the nucleus, and can also be
expressed at the cell surface or secreted into biological fluids via
non-classical secretory pathways (3). Depending on the cellular
component, gal-3 mediates both pro-and anti-apoptotic activity
(5). Gal-3 overexpression as well as prominent protumorigenic
effects have been shown in various tumors including pancreatic
ductal adenocarcinoma (PDAC) (6). Differential expression
profiling and microarray analysis revealed an enhanced gal-3
expression in the tissue of PDAC patients compared to that
of chronic pancreatitis (CP) patients, and a slightly increased
gal-3 expression in tissue of CP patients compared to healthy
donors (7–9).
PDAC is 4th leading cancer-related death due to an aggressive
growth, early metastatic dissemination and limited treatment
options (10, 11). Mutations in the pro-oncogene K-Ras (rat
sarcoma) together with a high Ras activity are suggested to
be associated with the pathogenesis of PDAC (12, 13). An
overexpression of gal-3 in pancreatic tumor tissue contributes
to PDAC progression via gal-3 binding to retaining Ras at
the plasma membrane maintaining Ras-signaling including
phosphorylation of Extracellular-signal Regulated Kinases (ERK)
and AKT and Ras-like (Ral) protein A activity (12–14).
In addition to the gal-3-mediated tumor transformation,
gal-3 secreted by tumor cells regulates immune cell activities
and contributes to immunosuppression (15). Extracellular gal-
3 binds glycosylated T cell surface receptors including the
receptor-linked protein tyrosine phosphatase CD45 expressed
on all leukocytes, integrins like CD11a (αL integrin), CD29 (β1
integrin), and CD49c (α3 integrin) and the T cell interaction
molecule CD7 (1, 16). Cross-linking glycoproteins at the T
cell surface induces anergy or apoptosis (15, 17–19). Gal-3
induces anergy of CD8T cells by distancing the T cell receptor
(TCR) from the CD8 molecule, and impairs NK cell activity by
Abbreviations: bsAb, bispecific antibody; BrHPP, bromohydrinpyrophosphate;
CRD, conserved carbohydrate recognition domains; DC, dendritic cell; ERK,
Extracellular-signal Regulated Kinases; gal-3, galectin-3; gal-9, galectin-9; HER-
2, Human epidermal growth factor receptor-2; LacNAc, N-acetyl-D-lactosamine;
mAb, monoclonal antibody; MICA, MHC class-I related chain A; n-BP,
aminobisphosphonate; NKG2D, natural-killer group 2, member D; PDAC,
pancreatic ductal adenocarcinoma; PI, propidium iodide; Ras, rat sarcoma;
TCR, T cell receptor; TIL, tumor-infiltrating lymphocytes; PAg, phosphorylated
antigen; PBMC, peripheral blood mononuclear cells; UKSH, University Hospital
Schleswig-Holstein.
inhibiting the interaction of the activating receptor natural-killer
group 2, member D (NKG2D) expressed on NK cells and the
heavily O-glycosylated tumor-derived MHC class I chain-related
protein (MIC) A (15, 20, 21).
In this context, γδ T lymphocytes, which highly express
NKG2D and infiltrate in PDAC tissues, are of high interest
(22–25). In this study, we focused on Vδ2-expressing γδ
T cells, which are specifically activated by pyrophosphate
intermediates of the prokaryotic non-mevalonate pathway of
cholesterol synthesis, and more importantly by dysregulated
mevalonate-pathway metabolites of transformed eukaryotic
cells (26, 27). Vδ2-expressing γδ T cells are a promising
cell population for T cell-based immunotherapy due to their
HLA-unrestricted target cell recognition and their enhanced
cytotoxicity against PDAC cells after application of targeted
biologicals such as bispecific antibodies (bsAb) (23, 28–30).
Here, we were interested in a possible induction of anergy
or apoptosis in Vδ2 γδ T cells by gal-3, which could explain
the observed exhaustion of anti-tumor responses of Vδ2
γδ T cells against PDAC cells unless bsAb were applied
(23, 30, 31).
MATERIALS AND METHODS
Cohort and Ethic Statement
The Department of Transfusion Medicine of the University
Hospital Schleswig-Holstein (UKSH) in Kiel, Germany, provided
leukocyte concentrates from healthy adult blood donors. In
addition, heparinized blood, serum samples and tumor tissue
from PDAC patients were obtained from the Department of
General and Thoracic Surgery (UKSH, Campus Kiel) and
from the Surgery Department of the Community Hospital in
Kiel distributed by the Biobank BMB-CC of the PopGen 2.0
Biobanking Network (P2N; UKSH, Campus Kiel) supervised
by Dr. C. Röder (Institute for Experimental Cancer Research,
Kiel, Germany). In total, 19 patients with histologically verified
PDAC (stage pT2-3, pN0-2, L0-1, V0-1) were enrolled. Serum
samples of 9 patients with histologically verified advanced
ovarian cancer (FIGO-stage IIIA-IV) were obtained from
the Department of Gynecology and Obstetrics of the UKSH
in Kiel. Pathological features of all tissues were assessed
according to WHO classification and UICC TNM staging.
None of the patients had undergone chemo- or radiotherapy
before this investigation. In accordance with the Declaration
of Helsinki, written informed consent was obtained from
all donors, and the research was approved by the relevant
institutional review boards (Ethic Committee of the Medical
Faculty of the CAU Kiel, code number: D405/10, D445/18,
and A110/99).
Ex vivo Isolation of Tumor-Infiltrating
Lymphocytes and Tumor Cells
Tumor tissue of PDAC patients removed during surgery
was dissected in the Institute of Pathology of the UKSH,
Campus Kiel. Tumor tissues (1–2 cm3) were washed (in
10 cm dishes) with PBS to remove blood debris. Subsequently,
the tumor tissues were minced into approximately 1 mm3
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pieces and treated with components A, H, and R of the
Tumor Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) for 1 h at 37◦C in 5mL PBS in a Gentle MACS
(Miltenyi Biotec). Digested cell suspension was then passed
through a 100µm cell strainer (Falcon, BD Biosciences),
visually controlled by light microscopy and centrifuged at
481 × g for 5min. Tumor cells as well as tumor-infiltrating
cells (TIL) were isolated by Ficoll-Hypaque (Biochrom, Berlin,
Germany) density gradient centrifugation. The purity of
the cells was determined by staining as described in the
flow cytometry section. Cells were cultured in RPMI 1640
supplemented with 2mM L-glutamine, 25mM HEPES, 100
U/mL penicillin, 100µg/mL streptomycin, 10% fetal bovine
serum (FBS, Thermo Fisher Scientific, Karlsruhe, Germany)
[complete medium].
Ex vivo isolated tumor cells and autologous TIL were
characterized phenotypically and functionally as described under
flow cytometry and functional assay section.
Separation of PBMC and T Cells and
Generation of Short-Term Activated T Cell
Lines
Peripheral blood mononuclear cells (PBMC) were isolated from
leukocyte concentrates or heparinized blood from PDAC patients
by Ficoll-Hypaque (Biochrom) density gradient centrifugation.
CD4 αβ T cells, CD8 αβ T cells and γδ T cells were positively
separated from freshly isolated PBMC by using the magnetic
cell separation system (Miltenyi Biotec). To isolate CD4 and
CD8T cells, cells were labeled directly with specific microbead-
coupled mAbs (CD4 and CD8 MicroBeads, Miltenyi Biotec).
To isolate γδ T cells, an indirect two-step process (anti-TCR
γδ micro-Bead Kit, Miltenyi Biotec) consisting of labeling the
γδ T cells with a specific hapten-coupled mAb followed by
staining the cells with FITC-labeled anti-hapten microbeads
were applied. The purity of the cells was >98% after their
magnetic separation.
To expand short-term activated CD4 or CD8 αβ T cell
lines or γδ T cell lines, 106 cells/mL were cultured in 24-well
plates in complete medium with 50 IU/mL rIL-2 (Novartis,
Basel, Switzerland) and stimulated with Activation/Expander
Beads (Miltenyi Biotec) with a one bead/one cell ratio for 3–
4 days for αβ T cells and 5–10 days for γδ T cells. The
beads were coated with 10µg/mL each anti-CD3 and anti-
CD28 mAbs and 0.5µg/mL anti-CD2 mAb overnight and used
as T cell receptor (TCR) stimulus. Alternatively, γδ T cell
lines were expanded by stimulation of PBMC with 2.5µM
aminobisphosphonate (n-BP) zoledronic acid (Novartis), which
induces a selective outgrowth of Vγ9 Vδ2-expressing γδ T cells.
Since resting, initially stimulated γδ T cells produced only very
low amounts of IL-2, 50 IU/mL rIL-2 was added every two
day. After 2 weeks, Vγ9Vδ2-expressing γδ T cell lines had a
purity of 60–99% and were labeled with anti-TCRαβ mAb clone
IP26 (BioLegend, San Diego, CA) and subjected to magnetic
separation in order to deplete remaining αβ T cells. After
αβ T cell depletion, Vγ9 Vδ2 γδ T cell lines had a purity
of 98–99%.
Established Tumor Cell Lines and Cell
Culture Conditions
Human PDAC cell lines Panc-1, PancTu-I, BxPC3, MiaPaCa-
2, Capan-2 cells derived from primary tumors as well as
Panc89 and Colo357 cells derived from a lymph node metastasis
were cultured in complete medium under regular conditions
(5% CO2, humidified, 37
◦C) (32). The PDAC cell lines were
kindly provided by Dr. C. Röder and Prof. Dr. A. Trauzold,
Institute for Experimental Cancer Research, Kiel, Germany.
0.05% trypsin/0.02% EDTA was used to detach adherent PDAC
cell lines from flasks. Absence of mycoplasma was routinely
confirmed by RT-PCR (Venor R© GEM classic, Minerva Biolabs
GmbH, Germany) and genotype by short tandem repeat analysis.
Flow Cytometry
In total, 1–2 × 106 PBMC and ex vivo isolated TIL were
stained by multi-color flow cytometry approach to distinguish
between diverse T cell subpopulations within different CD45+
leukocyte populations. Directly conjugated mAbs included
PerCP-labeled anti-CD45 clone 2D1, PE-Cy7-labeled anti-
pan TCRγδ clone 11F2 (both BD Biosciences, Heidelberg),
AF700-labeled anti-CD3 clone SK7, BV510-labeled anti-CD4
clone OKT4, APC-Cy7-labeled anti-CD8 clone SK1 (all three,
BioLegend), VioBlue-labeled anti-Vδ1 clone REA173 (Miltenyi
Biotec), PE-labeled anti-Vδ2 clone B6 (BD Biosciences), and
corresponding isotype controls (BD Biosciences or BioLegend).
To determine purity and expression of tumor-associated
antigens such as epithelial cell adhesion molecule (EpCAM)
and human epidermal growth factor receptor (HER)-2, 2 × 105
ex vivo isolated tumor cells derived from tumor tissues were
stained with mAbs as follows: PerCP-labeled anti-CD45 clone
2D1 (BD Biosciences), PE-Vio770-labeled anti-HER-2 clone
24D2 and APC-labeled anti-EpCAM clone REA-125 (both from
Miltenyi Biotec) followed by intracellular staining with FITC-
labeled anti-pan-Cytokeratin mAb clone CK3-6H5 (Miltenyi
Biotec). All ex vivo isolated tumor cells were pan-Cytokeratin+,
EpCAM+ and HER-2+, but did not express CD45. Additionally,
TIL, ex vivo isolated tumor cells and established PDAC cell
lines were also intracellularly stained with AF647-conjugated
anti-gal-3 (clone M3/38) or an appropriate isotype control (an
AF647-conjugated rat IgG2a mAb). Briefly, for the intracellular
staining, 2–5 × 105 cells were washed with staining buffer,
fixed and permeabilized with the Cytofix/Cytoperm kit (BD
Biosciences) for 20min following the procedures outlined by
the manufacturer. Thereafter, cells were washed twice with
Perm/Wash by centrifugation and stained with fluorochrome-
conjugated anti-gal-3 mAb or isotype control for 30min, washed
and measured.
All samples were analyzed on a FACS Calibur and a LSR-
Fortessa flow cytometer (both from BD Biosciences) using
CellQuestPro, Diva 8, or FlowJo software.
Cell Death Analysis by Flow Cytometry
Cell death analysis of γδ T cells was performed by combined
annexin-V FITC and propidium iodide (PI) staining. Briefly,
106/mL short-term activated γδ T cells were treated withmedium
or different concentrations (0.1 and 1µg/mL) of gal-3 or galectin
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(gal)-9 (both from BioLegend) in complete medium in 24-
well plates for 24 h. After incubation, cells were washed with
annexin-V binding buffer (MabTag, Friesoythe, Germany) and
stained with annexin-V FITC (1:10, MabTag) and PI (2µg/mL,
Serva; Heidelberg, Germany). After two washing steps, cells
were analyzed by flow cytometry, and the proportion of viable
(annexin-V− PI−), early apoptotic cells (annexin-V+ PI−) and
late apoptotic/necrotic cells (annexin-V+ PI+) was determined.
RNA Interference
In total, 1.5 × 105 PDAC cells were seeded in 12-well
plates, and incubated for 24 h in cell culture medium without
antibiotics. To downregulate gal-3 expression, the cells were
transfected with 12 pmol gal-3 Stealth RNAiTM siRNA or non-
targeting control pool (gal-3 sense; # 10620318, non-targeting
gal-3 antisense; # 10620319, both Thermo Fisher Scientific)
using 2 µL Lipofectamine R© RNAiMAX reagent (Thermo
Fisher Scientific) in 200 µL Opti-MEM medium for 10–20min
according to manufacturer’s protocol. The optimal time point
of downregulation was analyzed by flow cytometry and by
Western blot. The lowest gal-3 expression was detected 72 h
after transfection.
Functional Cell Culture Assay
In total, 1.25 × 105 PBMC of healthy donors or PDAC
patients were plated in complete medium with 50 IU/mL
rIL-2 in 96-round well-plates. γδ T cells within PBMC were
selectively activated by 300 nM phosphorylated antigen
(PAg) bromohydrinpyrophosphate (BrHPP, Innate Pharma,
Marseille, France) or 2.5µM n-BP zoledronic acid in
the absence or presence of different concentrations (0.01–
10µg/mL in logarithmic steps) of gal-3 (BioLegend). IFN-γ
was determined in the supernatant after 48 h using ELISA
(Supplemental Methods and Supplemental Figure 2). After
6–7 days, γδ T cell proliferation was analyzed as described
in the Cell proliferation assay section. Alternatively, 5–10 ×
103 established PDAC cells (wild type, control or gal-3 siRNA
transfected cells) were plated in 96-well flat-bottom plates in
complete medium. After 24 h, 2.5 × 105 PBMC were added
together with 50 IU/mL rIL-2 at an effector/target (E/T) ratio of
50:1 (PBMC/tumor cells) representing an effective E/T of 15:1–
40:1 for CD3T cells/tumor cells or of 1:4–10:1 for Vγ9Vδ2 T
cells/tumor cells. The effective E/T ratio was determined by
staining PBMC with anti-CD3, anti-Vγ9 and anti-Vδ2 mAb
using flow cytometry. In several experiments, resting or short-
term activated CD4 and CD8 positively isolated αβ T cells or
γδ T cells were used as effector cells at an E/T ratio of 50:1 for
resting cells or 5:1–40:1 for activated T cells. αβ T cells were
stimulated with Activation/Expander Beads (Miltenyi Biotec)
coated with 10µg/mL each of anti-CD3 and anti-CD28 mAbs
and 0.5µg/mL anti-CD2 mAb as αβ TCR stimulus or with
1µg/mL bsAb [HER2xCD3], which targets HER-2 expressed on
PDAC cells to CD3-expressing T cells (23, 30). γδ T cells were
cultured with 50 IU/mL IL-2 (for resting cells) and 12.5 IU/mL
(for activated cells), and were stimulated by 300 nM PAg BrHPP
or 2.5µM zoledronic acid or with the tribody [(HER2)2 xVγ9],
which targets HER2-expressing PDAC cells to Vγ9-expressing γδ
T cells (23, 30). As control, T cells were cultured and stimulated
in the absence of PDAC cells. γδ T cell proliferation was analyzed
after 6–7 days and αβ T cell proliferation after 3–4 days.
To analyze cell-cell contact dependency, 2 × 105 PancTu-I
cells plated in 24-well plates were cocultivated with unstimulated
or with PAg-stimulated short-term activated Vγ9Vδ2 γδ T cells
in the presence of 12.5 IU/mL IL-2 at an E/T ratio 40:1 separated
or not by a membrane with 0.4µm pores. As control, Vγ9Vδ2 γδ
T cells were cultured alone. After 24 h, gal-3 was measured in the
cell culture supernatant as described in the ELISA section.
For blocking assays, 2.5 × 105 PBMC were pre-incubated
in 110 µL of 10–20µg/mL of neutralizing antibodies including
anti-CD7 (clone M-T701), anti-CD11a (clone HI111), anti-
CD29 (clone Mab 13), anti-CD49c (clone C3 II.I) (all from
BD Biosciences) and anti-CD45 (clone HI 30, from BioLegend)
as well as appropriate isotypes mIgG1 (MOPC-21, BioLegend),
and rIgG2a (RTK2758, BioLegend). Alternatively, cells were
pretreated with a combination of 10µg/mL anti-CD29 mAb and
10µg/mL anti-CD49c mAb or appropriate controls. After 2 h of
incubation, 50 µL of pretreated PBMC were transferred to 5 ×
103 PancTu-I cells adhered overnight and stimulated with 2.5µM
zoledronic acid and 50 IU/mL of rIL-2. γδ T cell proliferation was
analyzed after 7 days.
For autologous assay system, 5 × 103 ex vivo isolated tumor
cells of PDAC patients were plated in 96-well flat-bottom plates in
complete medium. After 24 h, 2.5 × 105 autologous PBMC were
added together with 50 IU/mL rIL-2 at an effector/target (E/T)
ratio of 50:1 (PBMC/tumor cells) representing an effective E/T
of 1:1 or 0.5:1 (Vγ9Vδ2 T cells/tumor cells). For coculturing of
ex vivo isolated tumor cells of PDAC patients with autologous
TIL, we used a lower E/T ratio. This reduced E/T ratio resulted
from a low number of isolated TIL derived from 1 cm3 PDAC
tissue and from a different distribution of the cells within
the tumor tissue of PDAC patients. While 40–60% expressed
pan-Cytokeratin (detected as tumor cells) and 10–30% CD45
(detected as leukocytes), residual cells are tumor-associated cells,
which are part of the TIL population after Ficoll-Hypaque density
centrifugation of digested tumor tissue. 1.5× 105 ex vivo isolated
tumor cells of PDAC patients were plated in 96-well flat-bottom
plates in complete medium. After 24 h, 1.5× 103 autologous TIL
were added together with 50 IU/mL rIL-2 at an effector/target
(E/T) ratio of 1:4 (TIL/tumor cells) representing an effective E/T
of 1:40 or 1:400 (Vγ9Vδ2 T cells/tumor cells).
Functional read out systems included a proliferation assay and
measurement of gal-3 release as described as follows.
Cell Proliferation Assay
Proliferation was determined by measuring the absolute cell
number of viable CD3+ γδ or αβ T cells with a flow cytometric
method termed standard cell dilution assay (SCDA) after 6–8
days of culture. SCDA has been reported as a precise method to
specifically quantify any subset of phenotypically definable, viable
cells in heterogeneous populations (33). Briefly, co-cultured T
cells and tumor cells from 96-well round-bottom plates were
washed and stained with fluorescein isothiocyanate (FITC)-
labeled anti-CD3 mAbs (BD Biosciences, Heidelberg, Germany)
or AF488-conjugated anti-Vγ9 mAb clone 7A5 (34). After one
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washing step, cells were resuspended in 100 µL sample buffer
containing a defined number (104) of APC-labeled fixed standard
cells and 0.2µg/mL PI. The standard cells were purified T cells
that had been stained with APC-labeled anti-HLA class I mAb
clone W6/32 and anti-TCRαβ mAb clone IP26, and fixed in 1%
paraformaldehyde. The analysis on a flow cytometer allowed us to
simultaneously measure the expansion of viable CD3 or Vγ9 γδ
T cells (FITC+ or AF488+ PI− APC−) and standard cells (FITC−
FIGURE 1 | Intracellular galectin-3 expression in PDAC cells, and effect of recombinant galectin-3 on γδ T cell proliferation. (A) Histograms depicted are representative
results of indicated PDAC cells. Thin and bold lines represent isotype control and gal-3 expression (clone M3/38), respectively. (B) Median fluorescence intensity (MFI)
± SD (n = 3, duplicates) of gal-3 expression corrected by the MFI of the isotype control is shown for the indicated PDAC cell lines measured by FACS Calibur. (C)
PancTu-I cells were labeled with anti-gal-3 mAb (clone Gal397) and analyzed on the ImageStream® X Mark II. Five representative cells out of 5 × 103 recorded cells
are shown with bright field image (left side) and fluorescence image of gal-3 (right side). Scale bars represent 10µm. (D) 1.25 × 105 PBMC of paired healthy donors
(n = 4, different closed symbols), additional healthy donors (n = 7, two conc. of gal-3, closed circles) and paired PDAC patients (n = 4, open symbols) were
stimulated with 300 nM BrHPP with the different indicated concentrations of rgal-3 and 50 IU/mL rIL-2. After 6–7 days, the absolute cell number was determined as a
percentage of the medium control of the Vγ9 γδ T cells using SCDA. The mean ± SD of duplicates is shown. Statistical comparison of non-matched samples was
carried out parametrically by using one-way ANOVA followed by Tukey’s multiple comparison test. Significances are shown as P-value; *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
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FIGURE 2 | Coculture of PDAC cells with PBMC induces galectin-3 release and inhibition of γδ T cell proliferation. (A–C) In total, 5 × 103 of the indicated PDAC cells
were plated in complete medium. After 24 h (A,B) 2.5 × 105 PBMC (n = 4–7) or (C) 2 × 105 freshly isolated CD4 or CD8 αβ T cells or γδ T cells (Tc) (n = 6) were
added or cultured alone (medium). Cells were stimulated (A) with 2.5µM zoledronic acid in the presence of 50 IU/mL rIL-2, (B) with Activation/Expander Beads or (C)
with Activation/Expander Beads (TCR), 300 nM BrHPP (PAg) plus rIL-2 or 1µg/mL bsAb [HER2xCD3] for αβ T cells and [(HER2)2xVγ9] plus rIL-2 for γδ T cells. (A,B)
Vγ9 γδ T cell proliferation was determined after 6–7 days and αβ T cell proliferation after 3–4 days by SCDA. The means ± SD of duplicates are shown. (C) Cell culture
supernatants were collected after 72 h and released gal-3 was determined by ELISA. The bars represent the mean ± SD (n = 6), determined in duplicates. Statistical
comparison of (A) non-matched samples was carried out parametrically by using one-way ANOVA followed by Tukey’s multiple comparison test, and of (B,C)
matched samples also parametrically by using paired, two-tailed t-test. P-value; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and ns, non-significant.
or AF488− PI+ APC+). Based on the known number of standard
cells, the absolute number of viable CD3T cells or Vγ9 γδ T cells
in a given microculture well could be determined as follows: T
cell subset ratio = relative proportion of FITC+ or AF488+ PI−
APC− stained T cells/relative proportion of FITC− or AF488−
PI+ APC+ standard cells. The absolute number of FITC+ or
AF488+-stained T cells can be determined by multiplying the
T cell subset ratio with the number of standard cells per sample
(104 per 100 µL), since there is a linear correlation between the T
cell subset ratio and the absolute number of FITC+ or AF488+-
stained T cells as previously described (33). All samples were
analyzed on a FACSCalibur (BDBiosciences) using CellQuestPro
(including Batch-Setup function). Data were transferred to MS-
Excel for further analysis.
Enzyme-Linked Immunosorbent Assay
To quantify gal-3 released by PDAC cells (established cell
lines or ex vivo isolated tumor cells) or T cells alone or after
Frontiers in Immunology | www.frontiersin.org 6 June 2020 | Volume 11 | Article 1328
Gonnermann et al. Galectin-3 Inhibits γδ T Cell Proliferation
coculture of the different cell subsets, supernatants were collected
after different incubation times (24–96 h) and stored at −20◦C
until use. Additionally, gal-3 was determined within serum
samples of PDAC patients. Gal-3 was measured by sandwich
DuoSet ELISA kit (# DY1154 from R&D System, Wiesbaden,
Germany) in duplicates following the procedures outlined by
the manufacturer.
51Cr-Release Assay
Control or gal-3 siRNA transfected PDAC cells were labeled
with 50 µCi sodium 51Cr and 5 × 103 cells were used as
targets in a standard 4 h 51Cr release assay with titrated numbers
of short-term activated γδ T cells as effectors at an E/T ratio
of 50:1, 25:1, 12.5:1, and 6.25:1. Cells were (co)cultured in
medium or stimulated with the bsAb [(HER2)2xVγ9] for 4 h.
Supernatants were measured in a MicroBeta Trilux β-counter
(PerkinElmer, Hamburg, Germany). Specific lysis was calculated
as [(cpm test–cpm spontaneous)/(cpm max–cpm spontaneous)]
× 100, where spontaneous release was determined in medium
only and maximal release was determined in Triton-X-100 lysed
target cells. Spontaneous release did not exceed 15% of the
maximal release.
Imaging Flow Cytometry
The localization of proteins and their colocalization with other
proteins was quantified by an ImageStream R©X Mark II (Merck
Millipore, Burlington, MA, USA). This device combines flow
cytometry with microscopy by using a camera (with 405, 488,
562, 658, and 732 nm lasers) which takes high-resolution images
of each cell in up to six fluorescence channels and analyzes up
to 5,000 cells/s. To investigate the localization of gal-3 in PDAC
cells, 106 PDAC cells were stained with 10µg/mL anti-gal-3
mAb clone Gal397 (BioLegend) followed by 10µg/mL AF488-
conjugated goat anti-mouse secondary Ab (Thermo Fisher
Scientific) according to the protocol for intracellular staining (see
section flow cytometry). These images were then analyzed using
the IDEAS R© image analysis software.
Analysis of Synapse Formation Between
Tumor Cells and T Cells
To investigate the effect of synapse formation on the localization
of gal-3, PancTu-I cells were pelleted in 15mL Eppendorf tubes
and an equal number of short-term activated Vγ9Vδ2 γδ T cells
as effector cells were added. After 1, 3, 5, 10, 20, or 45min,
the cell conjugates were pelleted, fixed and permeabilized with
Cytofix/Cytoperm kit (BD Biosciences), and transferred to 96-
well plates for staining. Thereafter, cell conjugates were stained
with 10µg/mL anti-gal-3 Ab clone M3/38 (BioLegend) followed
by staining with 10µg/mL AF555-conjugated goat anti-rat
secondary Ab according to the protocol for intracellular staining.
After a further washing step, cell conjugates were stained with
an Ab mixture of 0.6µg/mL APC-conjugated anti-EpCAMmAb
clone REA-125 (Miltenyi) for tumor cells, 5µg/mL BV421-
conjugated anti-CD3 mAb clone UCHT-1 (BD Biosciences) for
T cells, and CruzFluor-488-conjugated phalloidin (1:5000, Santa
Cruz, Heidelberg) for actin-filament staining which is condensed
at the immunological synapse after tumor-T cell interaction.
FIGURE 3 | Galectin-3 knockdown in PancTu-I cells partially restores γδ
T cell proliferation within PBMC, and gal-3 release in coculture is cell
contact-dependent. (A) In total, 5 × 103 PancTu-I cells left non-transfected or
were transfected with either control siRNA or gal-3 siRNA and cultured in
complete medium 72h after transfection. After 24 h culture of PDAC cells, 2.5
× 105 PBMC were added (E/T 50:1) or cultured alone. After addition of 50
IU/mL rIL-2, cells were left unstimulated (med) or stimulated with 2.5µM
zoledronic acid (Z). After 6 days, the absolute cell number of the Vγ9 γδ T cells
was determined using SCDA. The mean ± SD of duplicates from 5 donors are
shown. (B) Short-term activated Vγ9Vδ2T cells were cultured with 50 IU/mL
rIL-2 alone and directly cocultured with 2 x 104 PancTu-I cells or indirectly
separated by a semipermeable membrane with 0.4µm pores of a transwell
insert in 24-well plates at an E/T ratio of 40:1. Cells were left untreated or
stimulated with PAg. After 24 h, gal-3 was measured in the cell culture
supernatant using ELISA. The means ± SD of 3 donors are shown. (A,B)
Statistical comparison of matched samples was carried out parametrically by
using paired, two-tailed t-test. P-value; *P < 0.05, **P < 0.01, ns, not
significant.
After washing, the cells weremeasured on ImageStream R©XMark
II (Merck Millipore) and conjugates were analyzed using the
IDEAS R© image analysis software. Firstly, tumor-T cell conjugates
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were identified via EpCAM, CD3, and phalloidin expression. To
define the cell periphery, a peripheral mask was then generated
based on the EpCAM signal, which marks the surface of the
tumor cell. For this purpose, a mask was defined with the Dilate-
function of the software that is one pixel larger than the mask
of the EpCAM signal. In addition, a mask was defined with
the Erode-function of the software that is six pixels smaller
than the mask of the EpCAM signal. Subtraction of the Erode-
generated mask from the Dilate-generated mask provided a ring-
shaped peripheral mask. The peripheral mask protrudes one
pixel beyond the cell and six pixels into the cell that allows the
determination of the gal-3 signal in the cell periphery.
Statistical Analysis
Shapiro-Wilk normality test was applied to analyze the normal
distribution assumption. The statistical analysis was assessed by
using Graph Pad Prism (Graph Pad Software, Inc., La Jolla,
CA, USA). The assumption of normal distribution was given
in all samples [Figures 1–4, 7, 8A,B (right panel)] with the
exception of parts of Figures 5A, 7 (γδ T cells), 8B (left panel) as
indicated in the appropriate figure legend. For parametric data of
non-matched datasets, a one-way ANOVA followed by Tukey’s
multiple comparison test was carried out. For parametric data
of matched datasets, a paired, two-tailed t-test was used. Non-
parametric data of matched datasets were analyzed by Wilcoxon
matched-pairs signed rank test. All statistical tests were two-sided
and the level of significance was set at α≤ 5%. Tests are indicated
in the figure legends where appropriate.
RESULTS
Galectin-3 as a Tumor-Suppressive
Mediator of (γδ) T Cell Proliferation
Recently, we and others demonstrated that γδ T cells infiltrate
the tumoral ducts of PDAC tissue (23, 24, 35). A possible reason
for the weak anti-tumor response of tumor-infiltrating γδ T cells
may be due to gal-3, which is described to be expressed by PDAC
cells and to contribute to tumor-mediated immune suppression
(13, 15). Regarding the expression of gal-3 in tumor cells, we
examined PDAC cells of different origin and differentiation
grade. Gal-3 was expressed very weakly in Panc1 and Panc89 cell
lines derived from primary tumors as well as in Colo357 cells
derived from a lymph node metastasis. Interestingly, all other
primary PDAC cells expressed intracellularly gal-3 to a higher
extent than Panc1, Panc89, and Colo357 cells (Figures 1A,B). In
order to obtain further information on possible functions of gal-
3, the localization of gal-3 in these PDAC cells was analyzed in
more detail. PancTu-I cells which showed a high expression of
gal-3 in comparison to Panc1 cells were labeled intracellularly
with anti-gal-3 mAb and analyzed on an ImageStream R© X
Mark II. A clear cytoplasmic, vesicular localization of gal-3 was
observed in all PDAC cells, also in Panc1 cells but to a much
lesser extent (Figure 1C, data not shown). A partial colocalization
of gal-3 with vesicular marker proteins such as the lysosomal
membrane-associated proteins CD107a (LAMP-1) and CD63
(LAMP-3) as well as vesicle synaptosome-associated protein
receptor Vti1b (expressed on vesicles of the trans-golgi network
or late endosomes), respectively, was observed. The expression
was found only in a small fraction of analyzed cells. However,
no colocalization was found with the recycling endosomes-
associated protein Rab11 (Supplemental Figure 1). This is in line
with the described non-classical secretory pathways for gal-3.
Interestingly, CD4 and CD8 TCRαβ T cells and TCRγδ T cells
also showed a vesicular expression of gal-3 (data not shown).
To examine whether recombinant gal-3 has an influence on
the proliferation of γδ T cells, PBMC of healthy donors and
PDAC patients were stimulated with PAg BrHPP and IL-2 in
the presence of different concentrations of recombinant gal-3.
Whereas, BrHPP and IL-2 induced a selective outgrowth of γδ
T cells within PBMC, the addition of increasing concentrations
of gal-3 to stimulated γδ T cells significantly reduced their
proliferation (Figure 1D). While the addition of 0.01µg/mL gal-
3 had no impact on γδ T cell proliferation, 0.1 and 1µg/mL
significantly impaired Vγ9Vδ2 T cell proliferation, respectively.
In addition, 10µg/mL gal-3 reduced the proliferation up to
60% compared to the medium control, suggesting a direct
inhibitory effect on the proliferative capacity of γδ T cells. In
contrast, the IFN-γ release after BrHPP and IL-2 stimulation
was not significantly influenced in the presence of different gal-3
concentrations (Supplemental Figure 2).
The stimulation of PBMC with zoledronic acid induced
an average 52-fold increase of the absolute cell number of
viable γδ T cells within PBMC (medium) compared to day
0 (Figure 2A). Interestingly, coculturing these PBMC with
weak gal-3 expressing Panc1 cells just leads to a minimal
decrease of γδ T cell proliferation. Those primary PDAC
cells, which expressed gal-3 to a higher extent, significantly
suppressed γδ T cell proliferation during coculture (Figure 2A).
Comparable results were obtained by stimulating all CD3-
expressing T cells via their TCR. The TCR-induced CD3T cell
proliferation was not influenced by the coculture with Panc1 cells
comparable to the stimulation without PDAC cells (medium),
while the coculture with highly gal-3-expressing PancTu-I cells
significantly reduced their proliferation (Figure 2B). Comparable
results were obtained with other PDAC cells such as Capan-2
and BxPC3 both expressing gal-3 to a higher extent compared
to Panc1 cells (data not shown). As already described, the
suppression of γδ T cell proliferation in the presence of
Colo357 cells is most likely due to an enhanced expression of
cyclooxygenase-2 in Colo357 cells which induce prostagladin
E2-mediated suppression (31, 36).
When PDAC cells or isolated T cells were cultured separately
or T cells were stimulated via TCR or by bsAb, the release of gal-
3 was weak, respectively (Figure 2C, upper panel, cells alone).
Determination of gal-3 release in supernatants after 24, 48, and
72 h revealed the highest gal-3 release after 72 h (Figure 2C).
Furthermore, we observed a slight increase of gal-3 secretion
after coculturing the T cells with Panc1 cells (Figure 2C, middle
panel). Interestingly, the gal-3 release significantly increased after
coculture of isolated γδ T cells with PancTu-I cells compared
to coculture with αβ T cells (Figure 2C, lower panel, medium).
After polyclonal stimulation of T cells via the TCR or by bsAb,
an enhanced gal-3 secretion was observed in the presence of
PancTu-I cells (Figure 2C, lower panel, TCR, bsAb).
Frontiers in Immunology | www.frontiersin.org 8 June 2020 | Volume 11 | Article 1328
Gonnermann et al. Galectin-3 Inhibits γδ T Cell Proliferation
FIGURE 4 | CD49c/CD29 play a role in the galectin-3 mediated inhibition of γδ T cell proliferation within PBMC. (A,B) In total, 5 × 103 PancTu-I cells were seeded for
24 h. 2.5 × 105 PBMC/well were pre-incubated with (A) the indicated concentrations of the displayed antibodies or appropriate isotype controls or (B) with 10µg/mL
anti-CD29 mAb together with 10µg/mL anti-CD49c mAb or appropriated isotype controls for 2 h. (A,B) Thereafter, PancTu-I cells were transferred and stimulated
with 2.5µM zoledronic acid and 50 IU/mL rIL- 2. After 7 days, the absolute cell number of Vγ9 γδ T cells was determined using SCDA. (A) The means ± SD of
duplicates of 2 donors are shown. (B) Each point represents an individual donor. Statistical comparison of matched samples was carried out parametrically by using
paired, two-tailed t-test. P-value; *P < 0.05.
Taken together, gal-3 was expressed in PDAC cells and T cells,
but was released only in small amounts by either cell population.
However, large amounts of gal-3 were released during coculture
of T cells together with highly gal-3 expressing PDAC cells such
as PancTu-I cells. PDAC cells with a high amount of gal-3 release
as well as soluble recombinant gal-3 inhibited the proliferation
of T cells.
Galectin-3 Released From Tumor Cells
Inhibits γδ T Cell Proliferation
The release of gal-3 is drastically enhanced in the coculture of
T cells and PancTu-I cells (Figure 2C). To examine whether
the released gal-3 is responsible for the inhibition of T cell
proliferation, gal-3 was knocked down by siRNA in PancTu-
I cells. The functionality of different gal-3 siRNAs in PancTu-
I cells was investigated on the basis of different applied
concentrations and at the optimal time point using flow
cytometry and Western blot analyses (Supplemental Figure 3).
After 72 h, a knockdown of 85–90% of gal-3 expression could
be shown after treatment with a concentration of 10–25 nM
gal-3 siRNA in PancTu-I cells compared to control siRNA
transfected cells (Supplemental Figure 3). Having defined the
appropriate conditions, non-transfected and control or gal-3
siRNA transfected PancTu-I cells were cocultured with PBMC.
After 6 days of coculture, a vigorous selective outgrowth of Vγ9
γδ T cells after stimulation with zoledronic acid compared to
the control was observed by measuring absolute cell number
of viable Vγ9 γδ T cells (Figure 3A). Because PBMCs from
different donors contain varying numbers of Vγ9 Vδ2 γδ T
cells, additionally, the x-fold increase of Vγ9 γδ T cells is
presented (Supplemental Figure 4A). Non-transfected PancTu-
I cells significantly inhibited the selective Vγ9 γδ T cell
proliferation, while the coculture of gal-3 siRNA transfected
PancTu-I cells partially, but significantly, restored the Vγ9 γδ
T cell proliferation compared to the coculture with control
siRNA transfected PancTu-I cells (Figure 3A). Similar results
were obtained by applying BrHPP instead of zoledronic acid for
stimulation of γδ T cell proliferation (Supplemental Figure 4B).
In contrast, Vγ9 γδ T cell proliferation after BrHPP or
zoledronic acid stimulation of PBMC cocultured with non-
transfected or control siRNA transfected Panc1 cells (with low
gal-3 expression) did not differ from coculture with gal-3 siRNA
transfected Panc1 cells (data not shown).
In order to induce a release of gal-3 by the PDAC cells
during the coculture with T cells, soluble factors of T cells, a
cell contact-dependent mechanism or both could play a role.
To examine a possible cell-cell contact dependence of gal-3
release, PancTu-I cells were directly cocultured with short-term
activated Vγ9Vδ2 γδ T cell lines or indirectly separated by a
semipermeable membrane of a transwell insert for 24 h. When
short-term activated Vγ9Vδ2 γδ T cell lines were cultured alone,
only a small amount of gal-3 was released after stimulation.
Release of gal-3 was significantly enhanced when cocultured with
PancTu-I cells but not after separating the PDAC cells from the
γδ T cell lines suggesting that the release of gal-3 is cell-cell
contact-dependent (Figure 3B).
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FIGURE 5 | Coculture of PancTu-I cells with activated γδ T cells increases galectin-3 release and its localization in the tumor cell periphery. (A) In total, 5 × 103
indicated PDAC cells were plated in complete medium. After 24 h, 2 × 105 short-term activated CD4 or CD8 αβ T cells or γδ T cells (Tc) (n = 6) were added or
cultured alone (cells alone). Cells were stimulated with Activation/Expander Beads (TCR), 300 nM BrHPP (PAg) plus 12.5 IU/mL rIL-2 or 1µg/mL bsAb [HER2xCD3]
for αβ T cells and [(HER2)2xVγ9] plus 12.5 IU/mL rIL-2 for γδ T cells. Cell culture supernatants were collected after 72 h and gal-3 was determined by ELISA. The
means ± SD of duplicates are shown. Statistical comparison was carried out parametrically by using paired, two-tailed t-test. P-value; *P < 0.05. As samples of CD8
and γδ T cells cultured in medium in comparison to bsAb did not follow a normal distribution, a Wilcoxon non-parametric, matched-pairs signed rank test was applied,
which revealed no significance (ns, non-significant). (B) PancTu-I cells alone or cocultured with short-term activated Vγ9 γδ T cells for the indicated time. Thereafter,
cells were stained with anti-gal-3 mAb (clone Gal397) followed by secondary goat-anti-mouse Ab and anti-EpCAM mAb (clone REA-125) for tumor cells, anti-CD3
(clone UCHT-1) for T cells and phalloidin for actin-filament staining and analyzed on the ImageStream® X Mark II. The fluorescence image of gal-3 plus overlays with
transmitted light image and peripheral mask of a representative PancTu-I cell with gal-3 expression predominately in the center or periphery is shown. In addition, the
mean ± SD of the intensity of gal-3 expression in the periphery of PancTu-I cells after addition of γδ T cells (n =3) are presented.
Similar effects were observed when using CD8 αβ T cell lines
instead of γδT cell lines or Capan-2 cells instead of PancTu-I cells
(Supplemental Figure 5).
In sum, coculturing T cells and PDAC cells led to
release of large amounts of gal-3. Knockdown of gal-3 in
PDAC cells revealed that tumor cells were the source of
gal-3 in coculture with T cells. The release of gal-3 by
PDAC cells in coculture was dependent on cell contact with
T cells, although it cannot be completely ruled out that
next to direct cell contacts, soluble factors released by T
cells may also be necessary to induce gal-3 release by the
tumor cells.
α3β1 Integrin (CD49c/CD29) Is Involved in
the Inhibition of T Cell Proliferation
Gal-3 can bind separately to various proteins expressed on T
cells such as CD7, CD11a (α-L integrin), CD29 (β1 integrin),
CD45 and CD49c (α3 integrin) which could be responsible
for the functional interaction of T cells and PDAC cells (1,
15, 17, 37). Therefore, PBMC were pretreated with relevant
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FIGURE 6 | Galectin-3 knockdown does not influence γδ T cell-mediated
cytotoxicity against PDAC cells, and does not induce cell death in γδ T cells.
(A) In total, 5 × 103 control (gray bars) or gal-3 siRNA transfected (striped
bars) PancTu-I cells were labeled with 51Cr and used as targets in a standard
51Cr release assay. Short-term activated γδ T effector cells were titrated at the
indicated E/T ratio and cultured in medium or stimulated with the bsAb
[(HER2)2xVγ9]. Mean values of triplicates (SD < 10%) are calculated. Mean ±
SD of 3 independent experiments with 3 different donors are shown. (B) 105
short-term activated γδ T cells were treated with the indicated concentrations
of gal-3 or gal-9 for 24 h. The cells were then labeled with annexin-V and
propidium iodide (PI) and analyzed by flow cytometry. The proportion of alive
(black bars, annexin-V− PI−), early apoptotic (light gray bars, annexin-V+ PI−)
and late apoptotic/necrotic (dark gray bars, annexin-V+ PI+) cells are shown
as the mean value of 3 donors in 3 independent experiments. SD was <10%.
antibodies against CD7, CD11a, CD29, CD45, and CD49c or
appropriate isotype controls at the indicated concentrations
for 2 h, respectively. Thereafter, PBMC were stimulated with
zoledronic acid combined with rIL-2 in the presence or
absence of PancTu-I cells. After 6 days of culturing, γδ T
cell proliferation was measured. As expected, the presence
of PancTu-I cells inhibited the zoledronic acid-induced γδ T
cell proliferation, and pretreatment with anti-CD7 and anti-
CD45 mAbs further enhanced this inhibition (Figure 4A).
Interestingly, only pretreatment of PBMC with anti-CD29 or
anti-CD49c mAbs partially restored the proliferation of γδ T
cells (Figure 4A). The partial restoration can be explained by
the observation that antibody pretreated PBMC in the absence
of cocultured PDAC cells already lead to a slight reduction of
γδ T cell proliferation compared to medium only (data not
shown). However, pretreatment with anti-CD49c mAb restored
the γδ T cell proliferation after coculture with PDAC cells
to a higher extent than pretreatment with anti-CD29 mAb
suggesting that α3 integrin plays a greater role than β1 integrin
(Figure 4A).
Interestingly, additional experiments that combined anti-
CD29 and anti-CD49c mAbs also revealed only a partial but
significant reconstitution of gal-3 mediated inhibition of γδ T cell
proliferation (Figure 4B).
Taken together, gal-3-mediated Vγ9 γδ T cell inhibition
by PDAC cells is partially and significantly restored by a
combination of neutralizing anti-CD49c and anti-CD29 mAbs.
Enhanced Galectin-3 Release of
Gal-3-Expressing PDAC Cells Cocultured
With γδ T Cells
In this study, we demonstrated that gal-3 release by PDAC cells is
enhanced after coculture with resting T cells compared to culture
of either cell population alone. While T lymphocytes including
γδ T cells in tumor patients are often suggested to be in an
activated state, we examined whether the release of gal-3 differs
in short-term activated T cells (Figure 5A) in comparison to
resting T cells (Figure 2C). Again, when PDAC cells or short-
term activated T cells were cultured in medium alone or after T
cell stimulation via TCR or by bsAb, the release of gal-3 was very
low (Figure 5A, upper panel, cells alone). While the coculture of
short-term activated T cells with Panc1 cells revealed no increase
in gal-3 release after 72 h (Figure 5A, lower left panel), gal-3
release was enhanced after coculturing short-term activated T
cells with PancTu-I cells as well as after their stimulation via the
TCR- or by bsAb (Figure 5A, right panel). In sum, we obtained
similar results with short-term activated T cells compared to
resting T cells.
Galectin-3 Is Relocalized Into the Cell
Periphery of PDAC Cells in Coculture With
T Cells
Hence, using ImageStream R© XMark II, we analyzed whether the
release of gal-3 by PDAC cells was induced by the formation of
an immunological synapse between interacting PDAC cells and T
cells. To this end, short-term activated γδ T cells were cocultured
with PancTu-I cells for 1–45min. To distinguish between the
two populations, T cells were stained with anti-CD3 mAb and
PancTu-I cells with anti-EpCAM mAb. In order to demonstrate
the formation of an immunological synapse, phalloidin was used
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FIGURE 7 | Monitoring of T lymphocyte subsets within blood and PDAC tissue, and galectin-3 serum levels. (A) The relative percentage of different T cell subsets
within ex vivo isolated PBMC and TIL of PDAC patients (n = 6) was determined by staining the cells with the indicated mAbs and analyzed by LSR Fortessa. A gate
was set on lymphocytes based on the side scatter properties and CD45 leukocytes to analyze γδ T cells within leukocytes. To distinguish between Vδ1 and Vδ2 within
the CD3/pan γδ TCR, a gate was set on CD3/pan γδ TCR-expressing T cells. For discrimination between CD4 and CD8 αβ T cells a gate was set on CD3T cells
(Continued)
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FIGURE 7 | excluding CD3/pan γδ TCR+ cells. The gating strategy is shown with PBMC of one patient. Each symbol presents the data of one donor, and the lines in
the boxes represent the median of different independent experiments. Statistical comparison of matched samples was carried out parametrically by using paired,
two-tailed t-test. P-value; *P < 0.05, **P < 0.01, ***P < 0.001. As γδ T cell samples did not follow a normal distribution, Wilcoxon non-parametric, matched-pairs
signed rank test was applied. P-value n.s., non-significant. (B) Gal-3 concentrations in serum samples from PDAC patients (n = 22), Ovarian cancer patients (OvCa, n
= 9) and age-matched healthy donors (HD, n =13) measured by ELISA are presented as dot plots. The filled dots are the patients presented also in (A). Samples
present no significant differences.
as a marker for filamentous (F)-actin. In addition, gal-3 was
stained to analyze whether gal-3 is released by PDAC cells when
the immunological synapse is formed (Figure 5B). Regardless of
the time point of γδ T cell addition,<1% of the PDAC and T cells
formed conjugates (data not shown). This could indicate a “kiss
and run mechanism” suggesting only a short contact between
PDAC and T cells. Interestingly, a different gal-3 localization was
observed depending on the coculture duration (Figure 5B). As
described in the Materials andMethods section, a peripheral ring
mask, which distinguishes between cell periphery and cell center,
was used to analyze the intensity of gal-3 staining. Figure 5B
shows two representative PancTu-I cells with considerable gal-3
expression in the cell center (Figure 5A, upper panel) as well as in
the cell periphery (Figure 5A, lower panel). The intensity of gal-3
expression within the peripheral mask of PancTu-I cells (Tumor
cells, TuC alone, n = 1) and of PancTu-I cells after the indicated
times of coculture with Vγ9 γδT cells (mean of n= 3 donors) was
calculated (Figure 5B). The gal-3 expression decreased slightly in
the cell periphery within the first 5min after the addition of the
γδ T cells which indicates a release of gal-3. Ten minutes after
γδ T cell addition, a time-dependent increase of gal-3 expression
intensity in the cell periphery was detected showing up to 30%
enhanced gal-3 expression intensity after 45min in comparison
to PDAC cells culture in the absence of γδ T cells. These data
indicate a possible relocalization of gal-3 from cell center toward
cell periphery or cell surface.
Overall, these results indicate that PDAC cells transport gal-
3 in vesicles to the cell surface after having direct cell contact
with γδ T cells. Consequently, gal-3 is released and inhibits γδ
T cell proliferation.
Bispecific Antibody Enhanced γδ T Cell
Cytotoxicity Against PDAC Cells
Independent of Galectin-3 Knockdown
We next analyzed whether the γδ T cell cytotoxicity was
influenced by gal-3 released by PDAC cells. Therefore, short-term
activated γδ T cells were cocultured with Cr51-labeled control or
gal-3 siRNA transfected PDAC cells at different effector/target
ratio, and cytotoxicity was analyzed using Cr51-release assay.
PancTu-I and Panc1 cells were almost resistant to γδ T cell-
mediated lysis unless bsAb were added to the culture [Figure 6A
and (38)]. The addition of bsAb significantly increased the γδ
T cell cytotoxicity independent of the gal-3 knockdown (striped
bars) in PDAC cells (Figure 6A) suggesting that gal-3 did not
influence γδ T cell cytotoxicity against PDAC cells. In addition,
CD107a-degranulation of γδ T cells was not significantly
modulated by gal-3 knockdown (Supplemental Figure 6).
Moreover, γδ T cell cytotoxicity was not influenced by gal-
3 in the presence or absence of bsAb. BsAb enhanced the
cytotoxic activity as well as the release of granzyme A and B
by γδ T cells (23, 24, 29). Similar to short-term activated γδ
T cells, tumor-infiltrating γδ T cells expressed high amounts of
granzymes suggesting a pre-activated state of these cells (39).
While preactivated γδ T cells are more susceptible to cell death,
we examined whether gal-3 induces apoptosis in these cells
because extracellular gal-3 has been described to mediate T cell
death (16, 40). To investigate apoptosis, short-term activated γδ
T cells were treated with the indicated concentration of gal-3 and
gal-9 as a control for 24 h. Annexin-V served as a marker for
apoptotic cells and annexin-V together with PI as markers for
late apoptotic cells (Figure 6B). Seventy percentage of the short-
term activated γδ T cells were viable (annexin-V− PI−) after
24 h culture in medium, whereas 6% were apoptotic (annexin-
V+ PI−) and 17% late apoptotic or necrotic (annexin-V+ PI+).
The addition of gal-3 as well as gal-9 at a low concentration
(0.1µg/mL) for 24 h did not influence the viability of the short-
term activated γδ T cells. Interestingly, the addition of 1µg/mL
gal-9 reduced the viability of the short-term activated T cells to
43%. In these cultures, the proportion of apoptotic cells increased
to 9% and of late apoptotic cells to 48%. Taken together, in
contrast to gal-9, gal-3 did not induce enhanced apoptosis in
short-term activated γδ T cells.
Reduced Number of Vδ2 γδ TIL Are
Suppressed in Their Proliferation by
Galectin-3 Releasing Autologous PDAC
Cells
In view of the gal-3 effects during the interaction of PDAC cells
and T cells isolated from peripheral blood of healthy donors or
PDAC patients, we speculated that the number of TIL could be
reduced due to a relevant amount of soluble gal-3 present in
PDAC patients.
By comparative immune profiling of TIL and PBMC of the
same PDAC patients, we observed a slight decrease of the CD3
γδ T cell percentage within TIL compared to PBMC (Figure 7A).
Additionally, we demonstrated an inversion of the Vδ1/Vδ2 T cell
ratio within CD3 γδ T cells when we compared the percentage
of the γδ T cell subsets of PBL and TIL from the same donor.
Similar to the inversion of the Vδ1/Vδ2 T cell ratio, there was
also an inversion of CD8/CD4T cells within CD3 αβ T cells.
We observed a significant increase of Vδ1 T cells and CD8 αβ T
cells within TIL compared to PBMC, whereas Vδ2 TIL and the
CD4 αβTIL significantly decreased in comparison to PBMC from
the same donor (Figure 7A). The distribution of CD8 and CD4
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FIGURE 8 | Coculture of ex vivo isolated PDAC cells with autologous PBMC or TIL inhibits γδ T cell proliferation and enhances release of galectin-3. (A) In total, 5 ×
103 or (B) 1.5 × 105 ex vivo isolated tumor cells (TuC) and (A) 2.5 × 105 autologous PBMC or (B) 1.5 × 103 autologous TIL were cultured alone or together in
complete medium or were stimulated with 2.5µM zoledronic acid with 50 IU/mL rIL-2 (Z). At day 0 and 11 days after culture, the absolute cell number of the Vγ9 γδ T
cells was determined using SCDA. Cell culture supernatants were collected after 96 h and galectin-3 was determined by ELISA. Each symbol presents the data of one
(Continued)
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FIGURE 8 | donor, and the lines represent the median of 4 different independent experiments. (A) Statistical comparison of matched samples was carried out
parametrically by using paired, two-tailed t-test. P-value; *P < 0.05, ***P < 0.001. (B) Wilcoxon non-parametric, matched-pairs signed rank test (left panel) or
parametric, matched-pairs, two-tailed t-test (right panel) was carried out. Samples present no significant differences. (C) Histograms are showing intracellular gal-3
expression stained with anti-gal-3 Ab (gray) compared to the appropriate isotype-control (unfilled) in pan-Cytokeratin+ tumor cells and CD45+ leukocytes of 2
representative donors (PDAC #1 and #2) out of 4.
αβ T cells was calculated within the CD3T cell populations by
excluding pan γδ T cells.
Analyzing circulating gal-3 in serum of patients with PDAC
or advanced ovarian cancer as well as in serum of age-matched
healthy donors revealed that gal-3 concentrations did not differ
between these groups (Figure 7B).
Since gal-3 serum levels did not differ between PDAC patients
and healthy donors, we asked whether ex vivo isolated tumor
cells release enhanced amounts of gal-3 after interaction with
autologous PBMC or TIL of PDAC patients, and thereby inhibit
γδ T cell proliferation. The stimulation of PBMC with zoledronic
acid and IL-2 in the absence of autologous tumor cells induced
a significant and selective outgrowth of Vγ9 T cells and PBMC
released very low amounts of gal-3 (Figure 8A). By coculturing
PBMC with autologous tumors cells without further stimulation,
Vγ9 T cells did not proliferate, and gal-3 release was slightly
enhanced in comparison to PBMC monoculture in the absence
of tumor cells (Figure 8A). However, after stimulating the
cocultured cells with zoledronic acid, γδ T cell proliferation was
significantly inhibited and a significantly enhanced gal-3 release
was observed (Figure 8A). We next asked if the proliferation of
autologous γδ TIL is affected in a similar way as γδ PBMC of the
same donor. Therefore, we cultured ex vivo isolated tumor cells
with autologous TIL, which comprises tumor-associated cells, in
IL-2 medium, and stimulated the culture with zoledronic acid
or medium (Figure 8B). Interestingly, the absolute cell number
of Vγ9 T cells within the TIL population was reduced after
zoledronic acid stimulation and, again, we observed an increase
in gal-3 release after addition of zoledronic acid to cocultured
cells as well as a strong intracellular gal-3 expression in tumor
cells and TIL in this autologous system (Figures 8B,C). Taken
together, the absolute number of viable Vγ9 T cells within the
TIL population was reduced comparable to the inhibition of Vγ9
γδ T cells within PBMC of the same donor after coculture with
zoledronic acid-stimulated autologous tumor cells. Interestingly,
zoledronic acid-stimulated autologous tumor cells cocultured
with TIL released an enhanced amount of gal-3 compared to the
medium control.
DISCUSSION
While an overexpression of gal-3 in PDAC tissues and a gal-3-
mediated suppression of CD8 TILs have been already described,
the gal-3 concentrations in the serum of pancreatic cancer
patients is discussed controversially (8, 9, 41, 42). This study
demonstrated that gal-3 is not increased in the serum of PDAC
patients, but it is highly expressed in ex vivo isolated PDAC
cells. In addition, gal-3 is not only expressed by PDAC cells
but also by T cells within PBMC and TIL. While gal-3 is only
released in small amounts by either cell population, the coculture
of both populations significantly enhanced the release of gal-
3. Interestingly, the stimulation of the cocultured cells further
increased gal-3 release which could be of high relevance for
clinical studies. Knockdown of gal-3 in PDAC cells demonstrated
that PDAC cells are the main source of gal-3. Gal-3 is released
by the majority of PDAC cells after interaction with T cells. It
effectively inhibited T cell proliferation, but not T cell cytotoxicity
regardless of presence of bsAb, which in turn potently enhanced
γδ T cell cytotoxicity. We demonstrated that extracellular gal-
3, released by PDAC cells after coculture with γδ T cells,
binds glycosylated γδ T cell surface receptor α3β1 integrin, and
contributes to inhibition of γδ T cell proliferation. This is of great
interest for an in vivo application of PAg or zoledronic acid where
the γδ T cell proliferation might be prevented if gal-3 is present.
Since the therapeutic options of PDAC treatment are
very limited, and the efficacy of chemotherapeutic agents
(e.g., gemcitabine) is unsatisfactory (10, 11), new therapeutic
approaches including application of bsAb or silencing of gal-3 in
PDAC cells could be of high clinical relevance (23, 30, 43, 44).
BsAb are designed to target T cells to tumor cells, thereby
enhancing T cell cytotoxicity against tumor cells. In contrast to
PAg, bsAb significantly increased γδ T cell cytotoxicity against
PDAC cells by inducing enhanced amounts of granzymes (23,
38). Additionally, we observed that bsAb did not further enhance
gal-3 release of PDAC cells cocultured with γδ T cells, in contrast
to PAg stimulation. Since the used bsAb are not designed to
significantly enhance T cell proliferation, the low number of
Vγ9 T cells within the tumors might be a problem. However,
our preliminary results suggest that tribody [(HER2)2xVγ9] can
potently enhance cytotoxic activity of low numbers of Vγ9 T cells
with TILs, which coexpress Vδ2 as well as Vδ1 (unpublished
observation). Since Vδ1 T cells are enriched within TIL of PDAC
patients, the impact of gal-3 on Vδ1 T cells is of high interest.
Unfortunately, the antigens which selectively induce a Vδ1 T cell
proliferation are so far unknown. Therefore, Vδ1 T cell expansion
within PBMC or TIL cannot be examined.
Regarding gal-3 as a potential novel target for PDAC therapy,
a transient siRNA mediated silencing of gal-3 in PDAC cells
suppresses their migration and invasion decreasing β-catenin,
which represents an important tumor cell invasion signal (45).
In addition, silencing of gal-3 in PDAC cells inhibits their
proliferation and invasion, and reduced tumor size and volume
in an orthotopic PDAC mouse model (13). The reports provide
clear evidence for gal-3 being an important player in PDAC
progression. In our study, we focused more on the role of gal-
3 in the interaction of PDAC cells and T cells with special
focus on γδ T cells, which infiltrate PDAC tissues, similarly
to CD8 αβ T cells (22–24, 35). All T cell subsets including
αβ and γδ T cells were inhibited in their proliferation after
coculture with gal-3 secreting PDAC cells, independent of
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the T cell activation state. Recently, Kouo and colleagues
reported about a gal-3-mediated inhibition in a CD8T cell-based
immunotherapy which aims to enhance the anti-tumor response
of cytotoxic CD8T lymphocytes. PDAC patients who respond to
a granulocyte-macrophage colony-stimulating factor (GMC-SF)-
secreting allogenic PDAC vaccine developed neutralizing gal-3
Ab after immunization. Gal-3 binds activated-committed CD8T
cells only in the tumor microenvironment and suppresses their
anti-tumor response via Lymphocyte-activation gene (LAG)-3
and by inhibiting the expansion of plasmacytoid dendritic cells
(42). Interestingly, gal-3 is described to contribute to a defect
in cytokine-secretion by CD8 TIL which mediates an anergic
state of these TIL due to defective actin rearrangement and a
disturbed triggering of Lymphocyte function-associated antigen
(LFA)-1 (αLβ2 integrin or CD11a/CD18) at the immunological
synapse (46). In their previous publications, Demotte et al.
observed a loss of colocalization of TCR and CD8 molecules
on CD8T cells that have low ability to bind tetramers and
a reduced cytokine release (20, 47, 48). Galectin-glycoprotein
lattices inhibited release but not intracellular cytokine expression
by affecting actin regulators Coronin 1a and Cdc42 Rho GTPase
and LFA-1 at the synapse (46).
Since gal-3 at physiological concentrations did not induce cell
death in γδ T cells in our experiments, we hypothesized that,
similar to CD8T cells, gal-3 has an immunosuppressive function
by inducing anti-proliferative signaling and consequently γδ
T cell anergy. However, treatment with physiological gal-3
concentrations did not significantly modulate IFN-γ release
or degranulation of γδ T cells, and the pre-treatment with
lactose did not restore the gal-3-mediated inhibition of γδ T
cell proliferation. Therefore, we suggest a different mechanism
of gal-3 on γδ T cell proliferation (within PBMC or TIL).
Knockdown of gal-3 in PDAC cells as well as neutralizing anti-
CD49c CD29 (α3β1 integrin) mAbs partially restored gal-3-
mediated inhibition of γδ T cell proliferation. Integrins such as
LFA-1 binding to the intercellular adhesion molecule (ICAM,
CD54) play an important role in the γδ T cell cytotoxicity
toward PDAC cells (49). However, the role of CD49c/CD29 in
the effector function of γδ T cells is less clear (50). CD49c/CD29
was expressed on the cell surface of resting γδ T cells, and
was downregulated after activation (51). LFA-1, CD49a/CD29
(α1β1 integrin) and CD49c/CD29 are described to bind gal-
3 (37, 52). The binding of gal-3 to CD49c/CD29 seems to be
dependent on the glycosylation of the glycosyltransferase by
β1,6-N-Acetylglucosaminyltransferase V (Mgat5) (53). Mgat5
is responsible for generating branched N-glycans that can
be elongated with N-acetyl-D-lactosamine (LacNAc) sequences
which bind the TCR. Gal-3 which also binds to LacNAc can
compete with TCR binding thereby inhibiting TCR clustering
(15). Knockdown of Mgat5 in mice prevents binding of gal-3
at the TCR, and improved the assembly of CD3 and TCR, and
thereby T cell proliferation (54). Additionally, the interaction
between poly LacNAc and gal-3 reduced the affinity of MHC
class-I related chain (MIC) A to NK cell receptor Natural-
killer group 2, member D (NKG2D), which impaired NK cell
cytotoxicity against tumor cells (21). Beside CD49c/CD29, gal-
3 can also bind to the γδ TCR or NKG2D expressed on Vδ2 γδ T
cells, and thereby increase the threshold for γδ T cell activation.
This results in an inhibition of T cell proliferation.
Chang et al. reported that α3β1 and α6β1 integrins
mediate laminin/merosin binding and function as costimulatory
molecules for human thymocyte proliferation (55). Our results
suggest that the binding of gal-3 to α3β1 integrin prevents the
proliferation-promoting effect of CD49c/CD29 on γδ T cells.
A blockade of the gal-3 α3β1 integrin interaction mediated by
applying a CD49c/CD29 mAb could also have an impact on
the proliferation-promoting effect of α3β1 integrin. This fact
together with binding of gal-3 to the TCR and/or NKG2D could
be an explanation for the incomplete restoration of the γδ T cell
proliferation after coculture with gal-3 secreting PancTu-I cells
after application of a neutralizing CD49c/CD29 mAb.
For the release of gal-3 by PancTu-I cells a direct cell
contact with T cells was necessary, which underscores the high
importance to examine the influence of cell-cell interactions. In
this study, the gal-3 intensity in the cell periphery of the PancTu-
I cells was decreased 1–3min after interaction with γδ T cells,
and then increased again within the next 45min. These data
suggest that stored gal-3 can be released very rapidly by tumor
cells after interaction with T cells and, thereafter, relocalization
of gal-3 toward the cell periphery is required. Interestingly, very
few synapses were formed between PDAC cells and γδ T cells
during this process indicating that gal-3 hindered the formation
of synapses between PDAC cells and T cells or a “kiss and run
mechanism” is involved in which γδ T cells bind briefly to the
tumor cell, kill it and move to the next tumor cell.
Since gal-3 has no signal sequence, the release via the
endoplasmic reticulum/trans-golgi network is very unlikely (56).
Furthermore, inhibitors of the classic secretory pathway such as
brefeldin A and monensin did also not inhibit the gal-3 release
by kidney cells suggesting that other mechanisms are involved
(57). In this context, the release by proteolysis or by exosomes
could be possible mechanisms. Gal-3 was already identified
in exosomes of tumor cells (58). Matrix metalloproteinases-
2 and−9, which both cleave gal-3, could release gal-3 bound
to receptors or extracellular matrix (59, 60). Exosomes are an
important component in immunological synapses between T
cells and antigen-presenting cells (61). An association of gal-3
with ALIX at the immunological synapse was shown in Jurkat
T cells. ALIX is a protein that is involved in the formation
of exosomes (62, 63). Therefore, we analyzed the localization
of gal-3 which was observed in vesicles of PDAC cells. To
characterize these vesicles in more detail, the colocalization of
gal-3 with the vesicular marker proteins CD107a (LAMP-1),
CD63 (LAMP-3), Rab11 and Vti1b was examined. Gal-3 has
been described in macrophages as a binding partner of the
lysosomal membrane-associated protein CD107a (64). However,
our results indicate that gal-3 did only slightly colocalize with
CD107a in PDAC cells. Differences in the colocalization of
gal-3 and CD107a in PDAC cells compared to macrophages
may be due to different glycosylation patterns of CD107a
in both cell populations. Different glycosylation patterns of
CD107a associated with a change in gal-3 colocalization has been
shown during the maturation of immature to mature dendritic
cells (DC) (65). In addition, gal-3 slightly colocalizes with
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other vesicular marker proteins such as lysosomal membrane-
associated protein CD63 and vesicle synaptosome-associated
protein receptor Vti1b expressed on vesicles of the trans-golgi
network or late endosomes was observed in only a fraction of
cells, but not with Rab11 expressed on recycling endosomes. In
other studies, gal-3 was detected in exosomes from DCs as well
as from bladder carcinoma cells, which suggests that the gal-
3 containing vesicles in PDAC cells may contain or resemble
exosomes (58, 66).
For PDAC, survival rates have not changed significantly in
the recent years and also treatment with immune checkpoint
inhibitors did not achieve improvements as observed in other
tumor entities (67). To enhance overall responsiveness of
immunotherapy, several clinical trials have started to combine
treatment with immune checkpoint inhibitors together with
galectin-3 inhibitor DG-MD-02 or GR-MD02 to enhance
therapeutic effects in other tumor entities (42). Thus, another
promising approach is the usage of bsAb which are able to
restore T cell cytotoxicity against PDAC cells of previously
non-reactive T cells. Our results indicate that gal-3 has
an immunosuppressive function on the proliferation of
circulating as well as tumor-infiltrating T cells and that T cell
cytotoxicity against PDAC cells can be significantly enhanced
by bsAb.
BsAb targeting γδ T cells provide a tool to enhance cytotoxic
capacity of γδ T cells, and gal-3 inhibitors to overcome
suppression of proliferation. Clinical studies are certainly
required to further investigate the therapeutic potential of
combing bsAb and galectin inhibitors.
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